coumarin has been researched along with tacrine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Al-Rashid, ZF; Beri, V; Cheung, J; Rosenberry, TL; Shiomi, K; Wildman, SA | 1 |
| Barbosa, G; Ceschi, MA; Dantas, RF; Dardenne, LE; de Salles, CMC; Guedes, IA; Lima, LM; Lopes, JPB; Lüdtke, DS; Ruaro, TC; Senger, MR; Silva, L; Silva-Jr, FP; Zimmer, AR | 1 |
| Kong, LY; Li, JY; Wang, XB; Xie, SS; Yang, L | 1 |
| Alipour, M; Foroumadi, A; Ghandi, M; Khoobi, M; Moradi, A; Nadri, H; Razavi, SF; Sakhteman, A; Shafiee, A | 1 |
| Peng, DY; Sun, Q; Yang, GF; Yang, SG; Yang, WC; Zhu, XL | 1 |
| Hamulakova, S; Hrabinova, M; Imrich, J; Janovec, L; Korabecny, J; Kristian, P; Kuca, K; Spilovska, K | 1 |
| Jiang, N; Kong, LY; Lan, JS; Li, ZR; Wang, KD; Wang, X; Xie, SS; Yu, W | 1 |
| Bednarikova, Z; Gazova, Z; Hamulakova, S; Holztragerova, M; Hsu, WT; Ulicna, K; Wang, SS; Wu, JW | 1 |
| Hamulakova, S; Hrabinova, M; Janockova, J; Janovec, L; Jun, D; Kuca, K; Sepsova, V; Soukup, O | 1 |
12 other study(ies) available for coumarin and tacrine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
The natural product dihydrotanshinone I provides a prototype for uncharged inhibitors that bind specifically to the acetylcholinesterase peripheral site with nanomolar affinity.
Topics: Acetylcholine; Acetylcholinesterase; Aflatoxin B1; Binding Sites; Binding, Competitive; Catalysis; Catalytic Domain; Cholinesterase Inhibitors; Crystallography, X-Ray; Furans; Humans; Hydrolysis; Kinetics; Models, Chemical; Phenanthrenes; Pyrans; Quinones; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity | 2013 |
Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.
Topics: | 2019 |
Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Cholinesterases; Coumarins; Dose-Response Relationship, Drug; Drug Design; Electrophorus; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Tacrine | 2013 |
Design, synthesis, docking study and biological evaluation of some novel tetrahydrochromeno [3',4':5,6]pyrano[2,3-b]quinolin-6(7H)-one derivatives against acetyl- and butyrylcholinesterase.
Topics: Acetylcholinesterase; Benzopyrans; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumarins; Drug Design; Enzyme Activation; Inhibitory Concentration 50; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Tacrine | 2013 |
Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Cholinesterase Inhibitors; Cholinesterases; Coumarins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Molecular Structure; Structure-Activity Relationship; Tacrine | 2014 |
Synthesis and biological evaluation of novel tacrine derivatives and tacrine-coumarin hybrids as cholinesterase inhibitors.
Topics: Acetylcholinesterase; Butyrylcholinesterase; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Coumarins; Drug Evaluation, Preclinical; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Structure-Activity Relationship; Tacrine | 2014 |
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cells, Cultured; Cholinesterase Inhibitors; Coumarins; Drug Design; Erythrocytes; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroblastoma; Piperazines; Tacrine | 2015 |
Lysozyme amyloid fibrillization in presence of tacrine/acridone-coumarin heterodimers.
Topics: Amyloid; Coumarins; Humans; Microscopy, Atomic Force; Muramidase; Tacrine | 2018 |
Tacrine-coumarin and Tacrine-7-chloroquinoline Hybrids with Thiourea Linkers: Cholinesterase Inhibition Properties, Kinetic Study, Molecular Docking and Permeability Assay for Blood-brain Barrier.
Topics: Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Coumarins; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Permeability; Structure-Activity Relationship; Tacrine; Thiourea | 2018 |